Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
View Patent ↗Compositions and methods of treating a central nervous system (CNS) disorder or mood disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising a melanocortin 5 receptor (MC5R) peptide ligand in a pharmaceutically acceptable carrier is administered to the subject. The MCSR peptide ligand is a selective MCSR antagonist, in which administration thereof to the subject can treat the CNS disorder or mood disorder with clinical improvement observed in a relatively short time.
1. A method of treating anxiety in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a composition comprising a melanocortin 5 receptor (MC5R) peptide ligand in a pharmaceutically acceptable carrier, wherein the MC5R peptide ligand is according to the following:
R 1 -Nle 4 - c [Asp 5 -Pro 6 -(NMe)D-Nal(2′) 7 -Arg 8 -Trp 9 -(NMe)Lys 10 ]-R 2
wherein R 1 is an acetyl, a glycosylated amino acid, —CO—(CH 2 ) n CH 3 , or —CO—(CH 2 ) n CF 3 , wherein n ranges from 1 to 6, and
wherein R 2 is an amide, —COOH, or —CH 2 OH.
2. The method of claim 1 , wherein the subject is a mammal.
3. The method of claim 2 , wherein the mammal is a human.
4. The method of claim 1 , wherein the MC5R peptide ligand is an antagonist of MC5R.
5. The method of claim 1 , wherein the composition is administered at least once daily, at least once every other day, or at least once weekly.
6. The method of claim 1 , wherein the composition is administered at a daily dose ranging from about 0.001 mg/kg to 100 mg/kg of body weight.
7. The method of claim 1 , wherein the composition is administered intranasally, intravenously, transdermally, or orally.
8. The method of claim 1 , wherein clinical improvement of the anxiety is observed in about 1 to 14 days.